By Rishika Sadam

HYDERABAD, India, Dec 3 (Reuters) – Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar with the matter said, as it seeks to strengthen its foothold in the world’s most populous nation.

India has the second-highest number of people with type 2 diabetes after China and rising obesity rates, making it a critical battleground for drugmakers vying for a share of the fast-growing weight-loss treatment market, which analysts expect to reach $150 billion annually by the end of the decade.

Ozempic, a once-weekly injectable approved by the U.S. Food and Drug Administration in 2017 for type 2 diabetes, has become a global bestseller and is widely used off-label for weight loss due to its appetite-suppressing

See Full Page